Therapy and treatment approaches

Intuition Beginner

Someone you care about is struggling. They cannot sleep. They have lost interest in things that used to bring them joy. They feel worthless. They have thought about not being alive anymore. What can be done?

This is the question that therapy and treatment try to answer. The approaches are diverse: talking with a trained therapist, changing patterns of thought and behavior, taking medication, joining a group of people facing similar challenges, involving family members in the healing process, and increasingly, using new technologies and substances under controlled conditions. No single approach works for everyone. Many people benefit from combining several.

The history of mental health treatment contains genuine progress and genuine harm. People have been helped by therapy and medication. People have also been harmed by forced treatment, overmedication, institutional abuse, and a mental health system that has historically pathologized normal responses to oppression. Both truths coexist. This unit covers both.

One point to establish at the outset: recovery is possible. Mental health conditions — including severe ones — are not necessarily lifelong sentences. Many people recover fully. Many more learn to manage their conditions and live rich, meaningful lives. The "chronic patient" narrative, while accurate for some, is not the only story, and presenting it as the default can become a self-fulfilling prophecy.

The major approaches

Psychoanalysis and psychodynamic therapy. Sigmund Freud developed psychoanalysis in the late nineteenth century. The core idea: unconscious conflicts — wishes, fears, and memories outside awareness — drive psychological distress. Psychoanalysis involves frequent sessions (often three to five times per week) over many years, using free association, dream analysis, and exploration of transference patterns (the patient's unconscious redirecting of feelings from past relationships onto the analyst). Psychodynamic therapy is a shorter, less intensive derivative that retains the focus on unconscious processes and relational patterns but typically involves weekly sessions over months rather than years.

Cognitive-behavioral therapy (CBT). Aaron Beck developed cognitive therapy in the 1960s. The core idea: psychological distress is maintained by distorted patterns of thinking — catastrophic predictions, all-or-nothing reasoning, mind-reading (assuming others think poorly of you), and personalization (blaming yourself for events outside your control). CBT teaches people to identify these cognitive distortions, test them against evidence, and replace them with more balanced thinking. Behavioral techniques — activity scheduling, exposure therapy, behavioral experiments — complement the cognitive work. CBT is structured, time-limited (typically 12-20 sessions), and focused on present-day problems rather than childhood origins.

Humanistic/client-centered therapy. Carl Rogers developed client-centered therapy in the 1940s and 1950s. The core idea: people have an innate tendency toward growth and self-actualization that is blocked by conditions of worth — internalized messages that they must be a certain way to be loved or accepted. Rogers proposed that three conditions in the therapeutic relationship are necessary and sufficient for change: unconditional positive regard (accepting the client without judgment), empathy (deeply understanding the client's subjective experience), and congruence (the therapist being genuine and authentic). Unlike CBT, client-centered therapy does not teach techniques or challenge thoughts. It creates conditions for the client to find their own answers.

Group therapy. Multiple clients meet with one or more therapists, typically weekly. The group itself becomes a microcosm of social life: members can practice interpersonal skills, receive feedback, discover they are not alone in their struggles, and develop mutual support. Irvin Yalom identified therapeutic factors specific to groups: universality (recognizing shared experiences), altruism (helping others), cohesiveness (belonging), and interpersonal learning.

Family therapy. Rather than treating an individual in isolation, family therapy works with the family system. The premise: psychological distress often reflects dysfunctional patterns of interaction within the family — enmeshment, disengagement, poor boundaries, communication failures, or rigid roles. Salvador Minuchin's structural family therapy, Murray Bowen's family systems theory, and Virginia Satir's humanistic approach are influential models. Family therapy is particularly important for adolescent eating disorders and child behavioral problems.

Medication

Psychiatric medications are among the most prescribed drugs in the world. The major classes:

• Antidepressants (SSRIs like fluoxetine/Prozac, sertraline/Zoloft; SNRIs; older tricyclics and MAO inhibitors). They work by altering neurotransmitter availability in the brain — primarily serotonin, norepinephrine, and dopamine. For moderate to severe depression, antidepressants outperform placebo. The effect is real but modest: meta-analyses suggest an average benefit of about 2-3 points on a 50-point depression scale above placebo. For mild depression, the evidence is weaker; the benefit over placebo shrinks toward zero.
• Antipsychotics (typicals like haloperidol; atypicals like risperidone, olanzapine). Used primarily for schizophrenia, bipolar disorder, and sometimes as adjuncts for depression. They reduce hallucinations and delusions in many patients but carry significant side effects: weight gain, metabolic syndrome, movement disorders (tardive dyskinesia), and in some cases emotional numbing.
• Anxiolytics (benzodiazepines like alprazolam/Xanax, diazepam/Valium; buspirone). They reduce anxiety quickly but benzodiazepines carry risks of dependence, tolerance, and withdrawal. Long-term use is controversial.

Medication is genuinely helpful for many people. It is also overprescribed. And it has been used as a tool of social control. These are not contradictory statements.

Emerging treatments

Psilocybin. A naturally occurring psychedelic compound found in certain mushrooms. Clinical trials at Johns Hopkins, Imperial College London, and elsewhere have shown that a small number of psilocybin sessions (typically two or three), combined with psychotherapy, can produce large and sustained reductions in depression, anxiety, and existential distress. A 2016 open-label study found that all 12 participants with treatment-resistant depression showed decreased symptoms one week after two psilocybin sessions, with effects persisting at three months for most. The mechanism may involve disrupting rigid patterns of negative thinking and increasing cognitive flexibility. Psilocybin remains a Schedule I substance in the United States, though several cities and states have decriminalized it or are in the process of doing so.

Ketamine. An anesthetic that, at sub-anesthetic doses, produces rapid antidepressant effects — often within hours, compared to the weeks required by conventional antidepressants. Ketamine works through the glutamate system rather than serotonin. Esketamine (Spravato), a nasal spray derivative, received FDA approval for treatment-resistant depression in 2019. Concerns include potential for abuse, dissociative side effects, and the fact that the antidepressant effect from a single dose is often temporary, requiring repeated administration.

Transcranial magnetic stimulation (TMS). A non-invasive procedure that uses magnetic fields to stimulate nerve cells in the prefrontal cortex. Approved by the FDA for treatment-resistant depression since 2008, TMS is used when medication and psychotherapy have not worked. It does not require anesthesia, has fewer systemic side effects than medication, but requires daily sessions for several weeks and is expensive.

Visual Beginner

The table below compares the major therapeutic approaches on their key features. No single approach is best for every person or every condition.

Approach	Core mechanism	Typical duration	Best evidence for	Key limitation
Psychodynamic	Unconscious conflict resolution	Months to years	Depression, personality disorders	Smaller evidence base; expensive
CBT	Cognitive restructuring + behavioral change	12-20 sessions	Anxiety, depression, insomnia, PTSD	May feel impersonal; less effective for complex trauma
Humanistic	Growth through empathy and acceptance	Variable	Mild-moderate distress; self-exploration	Less structured; weaker evidence for severe disorders
Group therapy	Peer support and interpersonal learning	Months	Substance use, social anxiety, grief	Not suitable for acute crisis; group composition matters
Family therapy	Changing relational patterns	Weeks to months	Adolescent disorders, eating disorders, family conflict	Requires family participation; not all families can or will
Medication	Neurochemical modulation	Ongoing (often)	Severe depression, bipolar, schizophrenia	Side effects; overprescription risk; does not teach coping

Treatment works best when it addresses biological, psychological, and social factors simultaneously. A person taking antidepressants who also receives therapy and has social support tends to do better than someone receiving any single intervention alone.

Worked example Beginner

Maria is a 34-year-old woman who has felt persistently sad for six months. She has lost interest in her hobbies, struggles to concentrate at work, wakes up at 4 AM every morning and cannot get back to sleep, and has gained 15 pounds from stress eating. She sometimes thinks her family would be better off without her, though she has no specific plan to harm herself. She has never seen a therapist.

A psychologist assesses Maria using a structured clinical interview and a depression inventory. Her scores indicate moderate-to-severe major depressive disorder.

What treatment would the evidence recommend?

For moderate-to-severe depression, the combination of medication (typically an SSRI) and CBT produces better outcomes than either alone. The American Psychological Association and the National Institute for Health and Care Excellence (NICE) in the UK both recommend combined treatment for this severity level.

CBT would help Maria identify and challenge the cognitive distortions maintaining her depression: "My family would be better off without me" (mind-reading — she has no evidence for this), "Nothing will ever get better" (catastrophic prediction), "I'm worthless" (all-or-nothing thinking). Behavioral activation — scheduling pleasurable and meaningful activities even when she does not feel like doing them — would address the withdrawal and inactivity that maintain depression.

An SSRI would address the neurochemical component, improving her sleep, appetite, and energy levels enough to engage more fully in therapy.

But the treatment plan should also consider Maria's context. Does she have health insurance that covers therapy? Does she have childcare during appointments? Does she have a supportive partner or family? Is she in a safe living situation? Does she belong to a cultural group that stigmatizes mental health treatment? Does she have a trusted primary care doctor who can prescribe and monitor medication? These practical questions often determine whether evidence-based treatment actually reaches the person who needs it.

Check your understanding Beginner

Formal definition Intermediate+

Psychotherapy: formal taxonomy

Psychotherapy is a structured, theoretically grounded intervention in which a trained practitioner uses psychological methods to help a client change thoughts, emotions, behaviors, or relational patterns. Psychotherapy is distinguished from informal support by four features: (1) a theoretical framework that explains why the client's problems exist and how change will occur, (2) a trained practitioner who applies that framework, (3) a structured format (session length, frequency, duration, techniques), and (4) a therapeutic relationship that is itself an instrument of change.

The major schools of psychotherapy can be organized by their level of theoretical integration:

1. Pure-form approaches adhere to a single theoretical model. Classical psychoanalysis, orthodox CBT, and client-centered therapy are examples.

2. Technical eclecticism uses techniques from multiple approaches without committing to a unified theory. Arnold Lazarus's multimodal therapy is an example.

3. Theoretical integration combines two or more theoretical frameworks into a coherent synthesis. Paul Wachtel's integration of psychoanalytic and behavioral perspectives is an example.

4. Common factors approaches focus on the elements shared across all effective therapies rather than on specific techniques.

The common factors model

Across hundreds of studies comparing different psychotherapy approaches, a consistent finding emerges: different therapies produce roughly equivalent outcomes for most conditions. This finding — called the "dodo bird verdict" after the character in Alice in Wonderland who declared "everybody has won and all must have prizes" — has been both influential and contested.

Saul Rosenzweig (1936) first proposed that common factors across therapies might explain their equivalent outcomes. Jerome Frank (1961) elaborated this idea, arguing that all effective therapies share: (1) an emotionally charged, confiding relationship with a helping person, (2) a healing setting, (3) a rationale or myth that explains the patient's distress, and (4) a procedure that requires active participation.

Bruce Wampold's meta-analytic work (2001, 2015) updated this framework with quantitative evidence. He estimated that specific therapeutic techniques account for roughly 5-15% of outcome variance, while common factors — the therapeutic alliance, client factors (motivation, severity, external resources), and expectancy (the client's belief that treatment will help) — account for the majority.

Key model: the therapeutic alliance

The therapeutic alliance, as defined by Edward Bordin (1979), has three components:

1. Agreement on goals. Therapist and client agree on what they are working toward.
2. Agreement on tasks. They agree on what they will do in and between sessions.
3. Emotional bond. There is trust, respect, and caring between them.

The alliance-outcome correlation (typically $r\approx 0.25$ to $0.30$) is one of the most robust findings in psychotherapy research. It holds across therapeutic modalities, client populations, and treatment settings. This does not mean the alliance causes improvement — it could be that clients who improve form better alliances, or that good early outcomes strengthen the alliance — but it is a consistent predictor.

Evidence-based practice: the three-legged stool

Evidence-based practice (EBP) in psychology, as defined by the American Psychological Association's 2005 Presidential Task Force, integrates three sources of information:

1. Best available research evidence. What do well-designed studies — RCTs, meta-analyses, systematic reviews — say about this treatment for this condition?
2. Clinical expertise. The clinician's trained judgment, accumulated experience, and ability to adapt general principles to the specific client.
3. Client characteristics, culture, and preferences. The client's values, cultural background, treatment history, and preferences about the type of treatment they want.

EBP is not simply "using treatments supported by RCTs." It is the integration of all three legs. A treatment with strong RCT support that conflicts with a client's cultural values or that a clinician is not competent to deliver is not evidence-based practice.

The pharmacotherapy evidence base

The randomized controlled trial (RCT) is the standard method for evaluating psychiatric medication. Patients are randomly assigned to receive either the active drug or a placebo (an inactive substance that looks identical). Neither the patient nor the prescribing physician knows which condition the patient is in (double-blind design). If the drug group improves significantly more than the placebo group, the drug is considered efficacious.

This design has real strengths: randomization balances known and unknown confounds, blinding reduces expectancy effects, and the placebo control quantifies the non-specific improvement that occurs simply from receiving treatment.

It also has limitations. Placebo effects in depression trials are large — typically accounting for 60-80% of the drug's apparent effect. The average drug-placebo difference on the Hamilton Depression Rating Scale is about 2-3 points on a 50-point scale. This does not mean antidepressants "do not work" — it means that a substantial portion of the improvement in medication trials comes from non-specific factors (hope, therapeutic contact, the act of taking a pill). For severe depression, the drug-placebo difference is larger and more clinically meaningful.

Publication bias inflates the apparent efficacy of antidepressants. Negative trials are less likely to be published. When the FDA analyzed both published and unpublished trial data (Turner et al., 2008), the proportion of positive trials dropped from 94% (published literature) to 51% (all registered trials).

Key experiment: the evidence hierarchy and its limits Intermediate+

The case of CBT's evidence base

CBT is described as the "most evidence-based" psychotherapy. This is true in a specific sense: more RCTs have tested CBT than any other therapy, and it has demonstrated efficacy for more conditions than any other single approach. The APA lists CBT as a first-line treatment for major depressive disorder, generalized anxiety disorder, social anxiety disorder, PTSD, obsessive-compulsive disorder, insomnia, and bulimia nervosa, among others.

The evidence base for CBT is also the product of a historical and political process. CBT is relatively easy to manualize — to write down in a step-by-step treatment guide — which makes it easy to study in RCTs. Psychodynamic therapy, by contrast, is harder to manualize and harder to study in the RCT framework. The result is an evidence base that reflects what is easy to measure, not necessarily what is most effective.

Furthermore, most CBT research has been conducted with WEIRD participants. The "most evidence-based" claim is more precisely stated as: CBT has the most evidence from randomized controlled trials conducted primarily with Western, Educated, Industrialized, Rich, Democratic populations. Whether CBT's specific techniques work equivalently across all cultures is an empirical question that has not been adequately tested. Cultural adaptations of CBT exist and show promise, but the evidence base for culturally adapted CBT is much smaller than the evidence base for standard CBT.

Evidence pattern: medication as genuine help, overprescription, and social control

Three things are simultaneously true about psychiatric medication.

First, medication is genuinely helpful for many people. Antidepressants reduce suffering for millions of people with moderate to severe depression. Antipsychotics allow many people with schizophrenia to live outside institutions. Lithium prevents manic episodes in bipolar disorder. These are real benefits that should not be minimized.

Second, medication is overprescribed. The threshold for prescribing has steadily lowered. Antidepressants are now the third most prescribed class of drugs in the United States, with about 13% of the population taking them. Prescription rates have increased roughly 400% since the late 1980s, far outpacing any plausible increase in the prevalence of depression. Direct-to-consumer pharmaceutical advertising (legal only in the United States and New Zealand) drives demand. The pharmaceutical industry has funded much of the research establishing efficacy, creating financial conflicts of interest. In some cases, the same data have been published multiple times in different journals to create the appearance of more positive studies than actually exist.

Third, medication has been used as a tool of social control. In prisons, psychiatric medication is sometimes administered involuntarily to manage behavior rather than to treat illness. Involuntary outpatient commitment laws allow courts to require people to take medication as a condition of living in the community. In some countries, political dissidents have been institutionalized and medicated. Within psychiatric institutions, forced medication — sometimes in doses that produce severe sedation — has been used for staff convenience rather than patient benefit. The line between treatment and control is not always clear, and the people most vulnerable to having that line crossed are those with the least power: prisoners, involuntarily committed patients, people in nursing homes, people without advocates.

Exercises Intermediate+

Competing perspectives: medication as help, overprescription, and control Master

Medication as genuine treatment

Psychiatric medication has transformed the lives of millions of people. Before the introduction of chlorpromazine (Thorazine) in 1954, people with schizophrenia were routinely institutionalized for life. Antipsychotics made it possible for many to live outside institutions — a genuine liberation. Lithium, discovered as a treatment for mania in 1949 and widely adopted by the 1970s, dramatically reduced the frequency and severity of manic episodes in bipolar disorder. SSRIs, introduced in the late 1980s, provided a safer alternative to the older tricyclic antidepressants (which were lethal in overdose) and made treatment accessible to a broader population.

For people with severe mental illness — psychotic disorders, bipolar disorder, severe depression with suicidality — medication is often not optional. It is the foundation without which other treatments (therapy, social support, vocational rehabilitation) cannot gain traction. Framing medication as inherently harmful risks denying effective treatment to people who need it.

The overprescription problem

The scale of psychiatric prescribing in the United States is striking. Approximately 1 in 6 Americans takes a psychiatric medication. Antidepressant use increased nearly 400% between 1988 and 2008. About 25% of people taking antidepressants have no diagnosed psychiatric condition.

Several factors drive overprescription:

Pharmaceutical marketing. Direct-to-consumer advertising creates demand by framing ordinary human distress — sadness, worry, difficulty concentrating, low energy — as medical conditions requiring medication. "Ask your doctor if [drug] is right for you" is designed to shift the conversation toward prescription.

The 15-minute med check. Insurance reimbursement structures favor brief medication management visits (typically 15 minutes) over longer psychotherapy sessions (45-50 minutes). A psychiatrist can see four medication-management patients in the time it takes to do one therapy session. The economic incentive favors prescription over conversation.

Diagnostic expansion. The DSM's successive editions have steadily increased the number of diagnosable conditions and lowered the threshold for diagnosis. Normal grief (now "persistent complex bereavement disorder"), normal childhood energy (now diagnosable as ADHD), and ordinary worry (now "generalized anxiety disorder") can all trigger medication.

Medication as social control

The use of psychiatric medication to control behavior rather than treat illness has a long history, and the distinction between "treatment" and "control" is contested.

Forced medication in prisons. The United States incarcerates more people than any other nation, and a disproportionate number of incarcerated people have mental health conditions — partly because the criminal justice system has become the de facto mental health system after the deinstitutionalization movement closed psychiatric hospitals without providing adequate community-based alternatives. In some prisons, antipsychotic medication is administered involuntarily, sometimes at doses that produce heavy sedation. The legal standard — that forced medication requires a finding of dangerousness — is applied unevenly.

Involuntary outpatient commitment. Also known as "assisted outpatient treatment" or "Kendra's Law" (named after Kendra Webdale, who was pushed in front of a subway train by a man with untreated schizophrenia). These laws allow courts to require people with mental illness to accept treatment — including medication — as a condition of living in the community. Proponents argue they prevent violence and homelessness. Critics argue they violate autonomy, are applied disproportionately to Black and poor people, and function as a less visible form of institutionalization.

Chemical restraint in institutions. In psychiatric hospitals and nursing homes, medication is sometimes used to manage agitation or non-compliance rather than to treat an underlying condition. The practice is widespread enough that the Centers for Medicare and Medicaid Services issued regulations limiting the use of antipsychotic medication in nursing homes — after finding that they were being prescribed to elderly patients with dementia at alarming rates, despite the drugs carrying a black-box warning for increased mortality in this population.

Cultural mistrust of the mental health system

BIPOC communities have reasons for skepticism about the mental health system that go beyond generalized distrust of institutions. The reasons are specific, documented, and rooted in historical events.

The Tuskegee Syphilis Study (1932-1972). The U.S. Public Health Service studied the progression of untreated syphilis in 399 Black men without their informed consent, actively withholding penicillin after it became the standard cure in 1947. The study ran for 40 years. The men were told they were receiving free healthcare. This was not a psychology study, but it is the most frequently cited reason Black Americans mistrust medical and research institutions, including mental health.

Forced sterilization. Throughout the twentieth century, state-sponsored eugenics programs sterilized over 60,000 Americans, disproportionately Black, Indigenous, Latino/a, and poor people, as well as people with mental illness and disabilities. These programs were justified by psychiatric diagnoses of "feeble-mindedness." The Supreme Court upheld forced sterilization in Buck v. Bell (1927), with Justice Holmes infamously declaring "three generations of imbeciles are enough."

Pathologizing the effects of slavery and racism. In the antebellum United States, the psychiatric establishment invented diagnoses to pathologize enslaved people who resisted captivity. Samuel Cartwright's "drapetomania" (1851) was a purported mental illness that caused enslaved people to run away; the prescribed treatment was "whipping the devil out of them." In the 1960s, as documented by Metzl, the presentation of schizophrenia in psychiatric literature shifted to emphasize hostility, aggression, and danger — qualities associated in the white cultural imagination with Black men protesting racial injustice. Black men were diagnosed with schizophrenia at rates far exceeding white men presenting with the same symptoms.

CIA MKULTRA. From the 1950s through the 1970s, the CIA funded psychological and psychiatric research on mind control, interrogation, and behavior modification. As covered in the introduction unit, psychologist Donald Ewen Cameron conducted experiments on psychiatric patients at McGill University without their informed consent, using drug-induced coma, massive electroconvulsive therapy, and repetitive taped messages intended to "depattern" personality. The subjects were vulnerable psychiatric patients who came to Cameron seeking treatment.

Contemporary disparities. Black Americans are less likely to receive psychotherapy and more likely to receive medication (often at higher doses) compared to white Americans with the same diagnoses. Black children are more likely to be diagnosed with conduct disorder (a diagnosis with behavioral and criminal-justice implications) while white children with similar symptoms are more likely to be diagnosed with ADHD (a diagnosis with treatment implications). These patterns persist after controlling for socioeconomic status.

Cultural mistrust is not irrational. It is a rational response to documented historical and ongoing harm. Effective treatment must acknowledge this reality rather than dismissing it as a barrier to be overcome.

Non-Western healing traditions

Western psychotherapy and pharmacology are not the only valid approaches to mental health, and they are not the oldest.

Buddhist mindfulness and meditation. Mindfulness — the practice of non-judgmental awareness of present-moment experience — has roots in Buddhist meditation traditions stretching back over 2,500 years. Jon Kabat-Zinn adapted mindfulness into Mindfulness-Based Stress Reduction (MBSR) in 1979 at the University of Massachusetts Medical Center, stripping it of its Buddhist religious context to make it acceptable in Western clinical settings. Mindfulness-Based Cognitive Therapy (MBCT), developed by Zindel Segal, Mark Williams, and John Teasdale in 2002, combines mindfulness with CBT techniques to prevent relapse in depression. Both MBSR and MBCT have substantial evidence bases.

This adaptation raises important questions. Has something been gained by making mindfulness accessible to secular Western audiences, or has something been lost by removing it from its ethical and philosophical framework? The Buddhist tradition in which mindfulness is embedded includes moral precepts (non-harming, generosity, truthful speech), community (the sangha), and wisdom (understanding the nature of suffering and impermanence). When mindfulness is extracted as a technique — a 10-minute daily exercise for reducing stress — it may lose the transformative depth that the full tradition offers. This is not an argument against MBSR or MBCT, which have helped many people. It is a reminder that the Western clinical appropriation of non-Western practices involves both translation and reduction.

Indigenous healing practices. Many Indigenous cultures have their own frameworks for understanding and addressing psychological distress. The Navajo (Dine) concept of hozho — harmony, balance, beauty — frames illness as a disruption of relational harmony between the individual, community, and natural world, requiring restoration through ceremony rather than individual treatment. The Lakota hanbleceya (crying for a vision) is a structured process of seeking guidance through fasting and prayer. The Māori practice of whānau ora places family wellbeing at the center of health rather than treating the individual in isolation.

These practices are not "primitive proto-therapy." They are sophisticated, culturally embedded systems of meaning-making and healing that have sustained communities for millennia. Western clinicians who work with Indigenous clients increasingly recognize the value of integrating traditional healing practices with evidence-based treatment — not as an add-on or afterthought, but as a genuine collaboration between knowledge systems.

Islamic counseling. Islamic approaches to mental health draw on the Quran, the Hadith (sayings of the Prophet Muhammad), and the jurisprudential tradition of Islamic ethics. Concepts like sabr (patience and perseverance in the face of hardship), tawakkul (trust in God), and shukr (gratitude) provide frameworks for coping with adversity. Islamic counseling integrates religious and spiritual practice with psychological insight. Some Muslim clients prefer to work with a therapist who shares their faith and understands the role of prayer, community (ummah), and religious practice in healing; others prefer a secular therapist who respects their faith without incorporating it into treatment. Both preferences are legitimate.

African traditional healing. Across sub-Saharan Africa, traditional healers have been the primary mental health providers for centuries. In many African countries, the ratio of traditional healers to population is far higher than the ratio of Western-trained mental health professionals. The World Health Organization estimates that 80% of Africans consult traditional healers as their first point of contact for health concerns, including mental health. African traditional healing typically frames psychological distress in relational and spiritual terms — ancestral discontent, social disharmony, spiritual attack — and treats it through communal rituals, herbal remedies, divination, and restoration of social bonds.

The relationship between Western psychiatry and African traditional healing has been marked by colonial dismissal and post-colonial negotiation. During the colonial period, European administrators and missionaries often criminalized traditional healing practices. In the post-colonial period, many African countries have worked to integrate traditional and Western approaches, recognizing that traditional healers are accessible, trusted, and embedded in their communities in ways that Western-trained clinicians often are not.

Culturally adapted therapies

Culturally adapted therapy modifies standard treatment approaches to be more congruent with a client's cultural values, beliefs, and practices. Griner and Smith's 2006 meta-analysis found that culturally adapted mental health interventions were four times more effective than non-adapted interventions for ethnic minority clients.

Adaptations can include: translating materials into the client's language (not just literal translation but cultural translation of concepts), incorporating cultural values (e.g., familism in Latino cultures, collectivism in many Asian cultures, the role of spirituality in many Black communities), involving family members in treatment where culturally appropriate, addressing experiences of discrimination and racism as legitimate sources of distress rather than "external" factors, and matching client and therapist on ethnicity or cultural background when possible.

The evidence for culturally adapted CBT is growing but still much smaller than the evidence base for standard CBT. This creates a dilemma: the treatment with the most evidence is the one least tested with the populations that most need culturally responsive care. Resolving this requires both more research with diverse populations and genuine collaboration between Western and non-Western healing traditions.

The prescription privilege debate

In the United States, psychologists (PhD or PsyD) cannot prescribe medication in most states — that authority belongs to psychiatrists (MD or DO) and, in some states, to psychiatric nurse practitioners and physician assistants. A debate has persisted since the late 1980s about whether psychologists should gain prescription authority.

Arguments for prescription privileges. Many areas of the United States have no psychiatrist within driving distance. Rural communities, Native American reservations, and poor urban neighborhoods face severe shortages. Allowing properly trained psychologists to prescribe medication could fill this gap. The Department of Defense conducted a pilot program in the 1990s in which psychologists received two years of pharmacology training and then prescribed medication under supervision. An independent evaluation found that their prescribing was safe and effective. Several states (New Mexico, Louisiana, Illinois, Iowa, Idaho, and others) have since granted prescription authority to psychologists with appropriate additional training.

Arguments against prescription privileges. Opponents argue that the pharmacological training in medical school and residency (four years of pharmacology-informed clinical experience) cannot be replicated by a two-year postdoctoral program. They worry about patient safety, medication interactions, and the risk that psychologists with prescription authority would default to medication rather than psychotherapy — becoming "junior psychiatrists" rather than preserving the distinctive psychological approach to treatment. Some also argue that the real problem is not the lack of prescribers but the lack of accessible mental health care in general, and that the solution is to train more psychiatrists and nurse practitioners rather than expanding psychologists' scope.

Recovery as the orienting goal

The recovery model, which originated in the psychiatric survivor movement of the 1980s and 1990s, reframes the goal of treatment from symptom elimination to meaningful life. Recovery is defined not as the absence of symptoms but as the ability to live a self-directed life despite the presence of a mental health condition.

Long-term outcome studies support this orientation. The Vermont Longitudinal Study followed 269 patients discharged from Vermont State Hospital and found that 50-68% achieved recovery or significant improvement over 20-30 years. The WHO's International Pilot Study of Schizophrenia found better outcomes in developing countries than in developed countries — a counterintuitive finding that may reflect the benefits of social integration, family involvement, and community belonging in cultures where people with mental illness are not isolated.

The recovery model does not deny the reality of severe mental illness or the value of medication. It insists that treatment should be oriented toward the life the person wants to live, not merely toward the suppression of symptoms. A person with schizophrenia who manages their symptoms with medication, works part-time, maintains friendships, and finds meaning in creative pursuits is recovered by this definition — even if they continue to hear voices occasionally.

Connections Master

• Psychological disorders 29.09.01. This unit's prerequisite. Therapy and treatment approaches are designed to address the disorders classified in 29.09.01. The classification system (DSM-5) determines what gets treated; the treatment approaches described here determine how.

• Neuroscience: brain and behaviour 29.02.01. Psychiatric medication acts on neurotransmitter systems covered in the neuroscience unit. Understanding how SSRIs affect serotonin reuptake, how antipsychotics block dopamine receptors, and how ketamine acts on the glutamate system requires the neuroscience foundation. The emerging treatments (psilocybin, ketamine, TMS) all have neurobiological mechanisms that connect to the neuroscience content.

• Social psychology 29.07.01. Stigma, prejudice, and discrimination — the social psychology of intergroup relations — are barriers to treatment. The stigma of mental illness, racial bias in diagnosis, and cultural mistrust of institutions are social-psychological phenomena with direct clinical implications.

• Cross-cultural and indigenous psychology 29.12.01. The non-Western healing traditions covered here (Buddhist mindfulness, Indigenous healing, Islamic counseling, African traditional healing) are developed in full in the cross-cultural psychology unit. The WEIRD critique of the CBT evidence base connects to the broader WEIRD critique introduced in 29.01.01 and elaborated in 29.12.01.

• Philosophy of science: demarcation and evidence 20.08.01. What counts as evidence in psychotherapy research? The RCT is the gold standard for medication trials, but is it the right standard for psychotherapy? The evidence hierarchy in clinical psychology — RCTs above naturalistic studies, meta-analyses above single studies — is a philosophical commitment about what counts as knowledge, not a neutral methodological fact.

• Bioethics [20.02.XX]. Forced treatment, involuntary commitment, the right to refuse medication, and the ethics of placebo-controlled trials all raise bioethical questions. The Tuskegee study, MKULTRA, and forced sterilization are case studies in research and clinical ethics.

• Health psychology and behavioral medicine. The biopsychosocial model of treatment connects to the broader study of how psychological, social, and biological factors interact in health and illness.

Historical and philosophical context Master

From moral treatment to the medical model

The modern history of mental health treatment in the West begins with the moral treatment movement of the late eighteenth and early nineteenth centuries. Philippe Pinel in France and William Tuke in England independently argued that people with mental illness should be treated with kindness, dignity, and meaningful activity rather than chained in asylums. The York Retreat, founded by Tuke in 1796, provided a quiet rural environment where residents gardened, socialized, and lived in a family-like setting. Moral treatment was not universally applied — it was often available only to wealthy patients — but it established the principle that the environment of care matters.

By the mid-nineteenth century, moral treatment gave way to the large state hospital system. Asylums grew overcrowded, understaffed, and increasingly custodial rather than therapeutic. By the early twentieth century, the standard treatment for severe mental illness was institutionalization — often for life. Treatments were few and often harmful: insulin coma therapy, lobotomy (for which Egas Moniz received the Nobel Prize in 1949), and prolonged restraint.

The introduction of chlorpromazine in 1954 began the pharmacological revolution. For the first time, medication could reduce psychotic symptoms enough for many patients to leave hospitals. The deinstitutionalization movement of the 1960s and 1970s, championed as liberation from oppressive institutions, released hundreds of thousands of patients from state hospitals. The promise was community-based care. The reality, in many cases, was that community mental health centers were never adequately funded, and former patients ended up homeless or incarcerated. The United States now has more people with serious mental illness in prisons than in psychiatric hospitals.

The talking cure: Freud and his legacy

Freud's "talking cure" — the idea that psychological distress could be alleviated through verbal exploration of unconscious conflicts — was revolutionary in an era when physical treatments (restraint, cold water immersion, ovarian compression to treat "hysteria") were the norm. Psychoanalysis dominated American psychiatry from the 1940s through the 1970s.

Several factors displaced psychoanalysis from its dominant position. The biological revolution demonstrated that medication could produce faster and more reliable improvement than years of analysis. Managed care and insurance companies refused to pay for long-term psychotherapy. The evidence-based practice movement demanded that treatments demonstrate efficacy in controlled trials — something that psychoanalysis, with its open-ended, non-manualized format, was poorly suited to provide.

Psychodynamic therapy — a shorter, more focused derivative of psychoanalysis — has demonstrated efficacy in modern trials. Shedler's 2010 meta-analysis found that the effect sizes for psychodynamic therapy were comparable to those for CBT, and that the benefits of psychodynamic therapy appeared to increase after treatment ended, possibly because patients internalized the capacity for self-reflection. Psychodynamic therapy is not obsolete; it is one legitimate option among many.

The cognitive revolution in therapy

Aaron Beck was originally trained as a psychoanalyst. In the 1960s, he set out to validate the psychoanalytic theory that depression is caused by unconscious hostility turned inward. His research did not support this theory. Instead, he found that depressed patients characteristically distorted their experience in predictable ways — catastrophizing, overgeneralizing, personalizing, and engaging in all-or-nothing thinking. Beck proposed that these cognitive distortions, not unconscious hostility, maintained depression, and that helping patients identify and correct these distortions would relieve their symptoms. Cognitive therapy was born.

Albert Ellis independently developed Rational Emotive Behavior Therapy (REBT) on similar principles, though with a more confrontational style. Beck's approach — collaborative, empirical, gentle in its challenging of thoughts — became the dominant form.

CBT's dominance is partly earned and partly an artifact of the research infrastructure. CBT is easy to manualize, easy to teach, and easy to study in RCTs. These are genuine virtues. They also mean that CBT has accumulated more evidence than approaches that are harder to operationalize. The evidence base is a product of both efficacy and measurability.

Rogers and the humanistic challenge

Carl Rogers proposed something radical in 1951: that the therapist does not need to be an expert who diagnoses and treats. Instead, the therapist needs to create conditions in which the client's own growth tendency can operate. Unconditional positive regard, empathy, and congruence — if genuinely present — are sufficient for therapeutic change.

Rogers's challenge to the medical model was both clinical and political. Clinically, he argued that the therapist's expertise is in the relationship, not in technique. Politically, he argued that the power differential inherent in the doctor-patient relationship — the doctor as expert, the patient as passive recipient — is itself harmful. Client-centered therapy democratized the therapeutic relationship.

The humanistic approach has been criticized for lacking specificity. Rogers's conditions are difficult to operationalize and measure, which limits the research base. But his insistence that the therapeutic relationship matters — that how the therapist is with the client is at least as important as what the therapist does — has been absorbed into virtually all subsequent therapeutic approaches. Even CBT, which originally presented itself as a purely technical intervention, now trains therapists in alliance-building as a core skill.

The placebo problem

The placebo effect in psychiatric treatment is large and unsettling. In antidepressant trials, placebo response rates typically range from 30-50%. For some conditions, the placebo response is indistinguishable from the drug response in a substantial proportion of patients.

Ted Kaptchuk (2001) argued that the double-blind, placebo-controlled RCT — the gold standard of evidence-based medicine — is not as methodologically pure as it appears. Placebo effects involve real neurobiological changes (endogenous opioid release, dopamine activation, changes in brain activity measurable by fMRI). They are not "just in the patient's head" in any dismissive sense — they are in the patient's brain, which is where the disorder also resides.

The therapeutic context itself may be the active ingredient. Being seen, being heard, being given an explanation for your suffering, being offered a treatment by a confident professional — these are therapeutic interventions regardless of whether the treatment is a pill, a conversation, or a ceremony. The common factors model suggests that psychotherapy works partly because it provides these contextual factors; psychiatric medication works partly because it provides them in pill form.

The replication crisis in psychotherapy research

Psychotherapy research faces many of the same problems documented in the broader replication crisis (see 29.01.01). Publication bias inflates effect sizes. Researcher allegiance effects — researchers who developed or favor a particular therapy tend to find it more effective — are well-documented. The "research therapy" delivered in RCTs (manualized, supervised, with fidelity checks) often differs substantially from the "real therapy" delivered in clinical practice, raising questions about external validity.

Cuijpers et al. (2010) found that the apparent efficacy of psychotherapy for adult depression was substantially inflated by publication bias, researcher allegiance effects, and the exclusion of studies with high dropout rates. After adjusting for these factors, the effect sizes shrank considerably — though they remained statistically significant and clinically meaningful.

The response has been to demand larger samples, preregistration, independent replication, and greater transparency about researcher allegiances and financial conflicts. These reforms are necessary but not sufficient. The deeper challenge is that psychotherapy research can never be fully double-blind: patients know they are receiving therapy, and therapists know what they are delivering. The RCT framework, borrowed from pharmacology, is an imperfect fit for psychotherapy.

Bibliography Master

• Freud, S., Studies on Hysteria (with Josef Breuer) (Deuticke, 1895). The founding work of psychoanalysis.

• Freud, S., "The Dynamics of Transference," Standard Edition 12 (1912), 97-108.

• Rogers, C. R., Client-Centered Therapy: Its Current Practice, Implications, and Theory (Houghton Mifflin, 1951).

• Rogers, C. R., "The Necessary and Sufficient Conditions of Therapeutic Personality Change," Journal of Consulting Psychology 21(2) (1957), 95-103.

• Beck, A. T., "Thinking and Depression: I. Idiosyncratic Content and Cognitive Distortions," Archives of General Psychiatry 9(4) (1963), 324-333.

• Beck, A. T., Cognitive Therapy and the Emotional Disorders (Penguin, 1979).

• Ellis, A., Reason and Emotion in Psychotherapy (Lyle Stuart, 1962).

• Frank, J. D., Persuasion and Healing: A Comparative Study of Psychotherapy (Johns Hopkins University Press, 1961).

• Rosenzweig, S., "Some Implicit Common Factors in Diverse Methods of Psychotherapy," American Journal of Orthopsychiatry 6(3) (1936), 412-415.

• Bordin, E. S., "The Generalizability of the Psychoanalytic Concept of the Working Alliance," Psychotherapy: Theory, Research and Practice 16(3) (1979), 252-260.

• Seligman, M. E. P., "The Effectiveness of Psychotherapy: The Consumer Reports Study," American Psychologist 50(12) (1995), 965-974.

• Wampold, B. E., The Great Psychotherapy Debate: Models, Methods, and Findings (Erlbaum, 2001).

• Wampold, B. E. and Imel, Z. E., The Great Psychotherapy Debate: The Evidence for What Makes Psychotherapy Work (2e, Routledge, 2015).

• Lambert, M. J., Bergin and Garfield's Handbook of Psychotherapy and Behavior Change (7e, Wiley, 2021).

• Shedler, J., "The Efficacy of Psychodynamic Psychotherapy," American Psychologist 65(2) (2010), 98-109.

• Kaptchuk, T. J., "The Double-Blind, Randomized, Placebo-Controlled Trial: Gold Standard or Golden Calf?," Journal of Clinical Epidemiology 54(6) (2001), 541-549.

• DeRubeis, R. J. et al., "Cognitive Therapy vs Medications for Depression: Treatment Outcome and Neural Mechanisms," Archives of General Psychiatry 62(4) (2005), 409-416.

• Cuijpers, P. et al., "The Effects of Psychotherapy for Adult Depression Are Overestimated: A Meta-Analysis of Study Quality and Funnel Plot Asymmetry," Psychological Medicine 39 (2010), 111-123.

• Turner, E. H. et al., "Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy," New England Journal of Medicine 358(3) (2008), 252-260.

• Prochaska, J. O. and Norcross, J. C., Systems of Psychotherapy: A Transtheoretical Analysis (9e, Oxford University Press, 2018).

• Griner, D. and Smith, T. B., "Culturally Adapted Mental Health Interventions: A Meta-Analytic Review," Psychotherapy 43(4) (2006), 531-548.

• Metzl, J. M., The Protest Psychosis: How Schizophrenia Became a Black Disease (Beacon Press, 2009).

• Washington, H. A., Medical Apartheid: The Dark History of Medical Experimentation on Black Americans from Colonial Times to the Present (Doubleday, 2006).

• Kabat-Zinn, J., Full Catastrophe Living: Using the Wisdom of Your Body and Mind to Face Stress, Pain, and Illness (Delacorte, 1990).

• Segal, Z. V., Williams, J. M. G., and Teasdale, J. D., Mindfulness-Based Cognitive Therapy for Depression: A New Approach to Preventing Relapse (Guilford Press, 2002).

• Carhart-Harris, R. L. et al., "Psilocybin with Psychological Support for Treatment-Resistant Depression: An Open-Label Feasibility Study," Lancet Psychiatry 3(7) (2016), 619-627.

• Zarate, C. A. et al., "A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression," Archives of General Psychiatry 63(8) (2006), 856-864.

• Yalom, I. D. and Leszcz, M., The Theory and Practice of Group Psychotherapy (5e, Basic Books, 2005).

• Minuchin, S., Families and Family Therapy (Harvard University Press, 1974).

• American Psychological Association Presidential Task Force on Evidence-Based Practice, "Evidence-Based Practice in Psychology: APA Presidential Task Force on Evidence-Based Practice," American Psychologist 61(4) (2006), 271-285.

• World Health Organization, Mental Health: Facing the Challenges, Building Solutions (WHO, 2005).